;PMID: 1655383
;source_file_953.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..39] = [t:0..39]
;1)sentence:[e:45..175] = [t:45..175]
;2)section:[e:179..218] = [t:179..218]
;3)section:[e:222..331] = [t:222..331]
;4)sentence:[e:335..431] = [t:335..431]
;5)sentence:[e:432..627] = [t:432..627]
;6)sentence:[e:628..798] = [t:628..798]
;7)sentence:[e:799..932] = [t:799..932]
;8)sentence:[e:933..1058] = [t:933..1058]
;9)sentence:[e:1059..1190] = [t:1059..1190]
;10)sentence:[e:1191..1314] = [t:1191..1314]
;11)sentence:[e:1315..1439] = [t:1315..1439]
;12)sentence:[e:1440..1512] = [t:1440..1512]
;13)sentence:[e:1513..1653] = [t:1513..1653]
;14)sentence:[e:1654..1753] = [t:1654..1753]
;15)sentence:[e:1754..1946] = [t:1754..1946]
;16)sentence:[e:1947..2043] = [t:1947..2043]
;17)sentence:[e:2044..2184] = [t:2044..2184]
;18)sentence:[e:2185..2409] = [t:2185..2409]
;19)section:[e:2413..2457] = [t:2413..2457]

;section 0 Span:0..39
;Endocrinology. 1991 Oct;129(4):1784-90.
(SEC
  (FRAG (RB:[0..13] Endocrinology) (JJ:[13..14] .) (CD:[15..19] 1991)
        (.:[20..28] Oct;129-LRB-) (CD:[28..30] 4-RRB-) (CD:[30..35] :1784)
        (HYPH:[35..36] -) (CD:[36..38] 90) (.:[38..39] .)))

;sentence 1 Span:45..175
;Ovine fetal adrenal synthesis of cortisol: regulation by adrenocorticotropin,
; angiotensin II and transforming growth factor-beta.
;[78..86]:substance:"cortisol"
;[102..121]:substance:"adrenocorticotropin"
;[124..138]:substance:"angiotensin II"
;[143..174]:substance:"transforming growth factor-beta"
(SENT
  (NP-HLN
    (NP
      (NP (JJ:[45..50] Ovine) (JJ:[51..56] fetal) (JJ:[57..64] adrenal)
          (NN:[65..74] synthesis))
      (PP (IN:[75..77] of)
        (NP (NN:[78..86] cortisol))))
    (::[86..87] :)
    (NP
      (NP (NN:[88..98] regulation))
      (PP (IN:[99..101] by)
        (NP
          (NP (NN:[102..121] adrenocorticotropin))
          (,:[121..122] ,)
          (NP (NN:[124..135] angiotensin) (CD:[136..138] II))
          (CC:[139..142] and)
          (NP
            (NML (VBG:[143..155] transforming) (NN:[156..162] growth)
                 (NN:[163..169] factor))
            (HYPH:[169..170] -) (SYM:[170..174] beta)))))
    (.:[174..175] .)))

;section 2 Span:179..218
;Rainey WE, Oka K, Magness RR, Mason JI.
(SEC
  (FRAG (NNP:[179..185] Rainey) (NNP:[186..188] WE) (,:[188..189] ,)
        (NNP:[190..193] Oka) (NNP:[194..195] K) (,:[195..196] ,)
        (NNP:[197..204] Magness) (NNP:[205..207] RR) (,:[207..208] ,)
        (NNP:[209..214] Mason) (NNP:[215..218] JI.)))

;section 3 Span:222..331
;Department of Obstetrics and Gynecology, University of Texas Southwestern 
;Medical Center, Dallas 75235-9032.
(SEC
  (FRAG (NNP:[222..232] Department) (IN:[233..235] of)
        (NNP:[236..246] Obstetrics) (CC:[247..250] and)
        (NNP:[251..261] Gynecology) (,:[261..262] ,) (NNP:[263..273] University)
        (IN:[274..276] of) (NNP:[277..282] Texas) (NNP:[283..295] Southwestern)
        (NNP:[297..304] Medical) (NNP:[305..311] Center) (,:[311..312] ,)
        (NNP:[313..319] Dallas) (CD:[320..325] 75235) (HYPH:[325..326] -)
        (CD:[326..330] 9032) (.:[330..331] .)))

;sentence 4 Span:335..431
;An increase in cortisol production by the fetal adrenal cortex is an
;important  prepartum event.
;[350..358]:substance:"cortisol"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[335..337] An) (NN:[338..346] increase))
      (PP (IN:[347..349] in)
        (NP
          (NP (NN:[350..358] cortisol) (NN:[359..369] production))
          (PP (IN:[370..372] by)
            (NP (DT:[373..376] the) (JJ:[377..382] fetal)
                (JJ:[383..390] adrenal) (NN:[391..397] cortex))))))
    (VP (VBZ:[398..400] is)
      (NP-PRD (DT:[401..403] an) (JJ:[404..413] important)
              (JJ:[415..424] prepartum) (NN:[425..430] event)))
    (.:[430..431] .)))

;sentence 5 Span:432..627
;The increase in ovine fetal adrenal synthesis of cortisol  appears to rely in
;part on the ACTH induction of 17 alpha-hydroxylase cytochrome  P-450 (P-45017
;alpha) which occurs before parturition.
;[481..489]:substance:"cortisol"
;[522..526]:substance:"ACTH"
;[540..578]:cyp450:"17 alpha-hydroxylase cytochrome  P-450"
;[580..593]:cyp450:"P-45017 alpha"
(SENT
  (S
    (NP-SBJ-2
      (NP (DT:[432..435] The) (NN:[436..444] increase))
      (PP (IN:[445..447] in)
        (NP
          (NP (JJ:[448..453] ovine) (JJ:[454..459] fetal)
              (JJ:[460..467] adrenal) (NN:[468..477] synthesis))
          (PP (IN:[478..480] of)
            (NP (NN:[481..489] cortisol))))))
    (VP (VBZ:[491..498] appears)
      (S
        (NP-SBJ-2 (-NONE-:[498..498] *))
        (VP (TO:[499..501] to)
          (VP (VB:[502..506] rely)
            (PP (IN:[507..509] in)
              (NP (NN:[510..514] part)))
            (PP-CLR (IN:[515..517] on)
              (NP
                (NP
                  (NP (DT:[518..521] the) (NN:[522..526] ACTH)
                      (NN:[527..536] induction))
                  (PP (IN:[537..539] of)
                    (NP
                      (NP (CD:[540..542] 17) (NN:[543..560] alpha-hydroxylase)
                          (NN:[561..571] cytochrome) (NN:[573..578] P-450))
                      (NP (-LRB-:[579..580] -LRB-)
                         (NN:[580..587] P-45017) (SYM:[588..593] alpha)
                        (-RRB-:[593..594] -RRB-)))))
                (SBAR
                  (WHNP-1 (WDT:[595..600] which))
                  (S
                    (NP-SBJ-1 (-NONE-:[600..600] *T*))
                    (VP (VBZ:[601..607] occurs)
                      (PP-TMP (IN:[608..614] before)
                        (NP (NN:[615..626] parturition))))))))))))
    (.:[626..627] .)))

;sentence 6 Span:628..798
;In the present study we  examined the effect of ACTH treatment on cortisol
;production and P-450(17) alpha  expression using primary cultures of ovine
;fetal adrenal cells.
;[676..680]:substance:"ACTH"
;[694..702]:substance:"cortisol"
;[718..733]:cyp450:"P-450(17) alpha"
(SENT
  (S
    (PP (IN:[628..630] In)
      (NP (DT:[631..634] the) (JJ:[635..642] present) (NN:[643..648] study)))
    (NP-SBJ (PRP:[649..651] we))
    (VP (VBD:[653..661] examined)
      (NP
        (NP (DT:[662..665] the) (NN:[666..672] effect))
        (PP (IN:[673..675] of)
          (NP (NN:[676..680] ACTH) (NN:[681..690] treatment))))
      (PP (IN:[691..693] on)
        (NP
          (NP (NN:[694..702] cortisol) (NN:[703..713] production))
          (CC:[714..717] and)
          (NP
             (NN:[718..727] P-450-LRB-17-RRB-) (SYM:[728..733] alpha)
            (NN:[735..745] expression))))
      (S-MNR
        (NP-SBJ (-NONE-:[745..745] *))
        (VP (VBG:[746..751] using)
          (NP
            (NP (JJ:[752..759] primary) (NNS:[760..768] cultures))
            (PP (IN:[769..771] of)
              (NP (JJ:[772..777] ovine) (JJ:[778..783] fetal)
                  (JJ:[784..791] adrenal) (NNS:[792..797] cells)))))))
    (.:[797..798] .)))

;sentence 7 Span:799..932
;In addition, we  examined the effects of angiotensin II (A-II) and
;transforming growth  factor-beta (TGF beta) on ACTH-treated cells.
;[840..854]:substance:"angiotensin II"
;[856..860]:substance:"A-II"
;[866..898]:substance:"transforming growth  factor-beta"
;[900..908]:substance:"TGF beta"
;[913..917]:substance:"ACTH"
(SENT
  (S
    (PP (IN:[799..801] In)
      (NP (NN:[802..810] addition)))
    (,:[810..811] ,)
    (NP-SBJ (PRP:[812..814] we))
    (VP (VBD:[816..824] examined)
      (NP
        (NP (DT:[825..828] the) (NNS:[829..836] effects))
        (PP (IN:[837..839] of)
          (NP
            (NP
              (NP (NN:[840..851] angiotensin) (CD:[852..854] II))
              (NP (-LRB-:[855..856] -LRB-) (NN:[856..860] A-II)
                  (-RRB-:[860..861] -RRB-)))
            (CC:[862..865] and)
            (NP
              (NP
                (NML (VBG:[866..878] transforming) (NN:[879..885] growth)
                     (NN:[887..893] factor))
                (HYPH:[893..894] -) (SYM:[894..898] beta))
              (NP (-LRB-:[899..900] -LRB-)
                 (NN:[900..903] TGF) (SYM:[904..908] beta)
                (-RRB-:[908..909] -RRB-)))))
        (PP (IN:[910..912] on)
          (NP
            (ADJP (NN:[913..917] ACTH) (HYPH:[917..918] -)
                  (VBN:[918..925] treated))
            (NNS:[926..931] cells)))))
    (.:[931..932] .)))

;sentence 8 Span:933..1058
;We have demonstrated previously  that these factors modulate P-450(17 alpha)
;levels in adult ovine and bovine  adrenal cells.
;[977..984]:substance:"factors"
;[994..1009]:cyp450:"P-450(17 alpha)"
(SENT
  (S
    (NP-SBJ (PRP:[933..935] We))
    (VP (VBP:[936..940] have)
      (VP (VBN:[941..953] demonstrated)
        (ADVP-TMP (RB:[954..964] previously))
        (SBAR (IN:[966..970] that)
          (S
            (NP-SBJ (DT:[971..976] these) (NNS:[977..984] factors))
            (VP (VBP:[985..993] modulate)
              (NP
                 (NN:[994..999] P-450)
                (PRN (-LRB-:[999..1000] -LRB-)
                  (NP (CD:[1000..1002] 17) (SYM:[1003..1008] alpha))
                  (-RRB-:[1008..1009] -RRB-))
                (NNS:[1010..1016] levels))
              (PP-LOC (IN:[1017..1019] in)
                (NP
                  (NP
                    (ADJP-2 (JJ:[1020..1025] adult))
                    (JJ:[1026..1031] ovine)
                    (NML-1 (-NONE-:[1031..1031] *P*)))
                  (CC:[1032..1035] and)
                  (NP
                    (ADJP-2 (-NONE-:[1035..1035] *P*))
                    (JJ:[1036..1042] bovine)
                    (NML-1 (JJ:[1044..1051] adrenal) (NNS:[1052..1057] cells))))))))))
    (.:[1057..1058] .)))

;sentence 9 Span:1059..1190
;Fetal ovine adrenal cells were isolated from 126- to 130-day  fetuses (term =
;144 +/- 3 days) and placed in monolayer cell culture.
;[1104..1115]:quantitative-value:"126- to 130"
;[1116..1119]:quantitative-units:"day"
;[1137..1146]:quantitative-value:"144 +/- 3"
;[1147..1151]:quantitative-units:"days"
(SENT
  (S
    (NP-SBJ-1 (JJ:[1059..1064] Fetal) (JJ:[1065..1070] ovine)
              (JJ:[1071..1078] adrenal) (NNS:[1079..1084] cells))
    (VP
      (VP (VBD:[1085..1089] were)
        (VP (VBN:[1090..1098] isolated)
          (NP-1 (-NONE-:[1098..1098] *))
          (PP (IN:[1099..1103] from)
            (NP
              (NML
                (QP (CD:[1104..1107] 126) (HYPH:[1107..1108] -)
                    (TO:[1109..1111] to) (CD:[1112..1115] 130))
                (HYPH:[1115..1116] -) (NN:[1116..1119] day))
              (NNS:[1121..1128] fetuses)
              (PRN (-LRB-:[1129..1130] -LRB-)
                (S
                  (NP-SBJ (NN:[1130..1134] term))
                  (VP (SYM:[1135..1136] =)
                    (NP-PRD
                      (QP (CD:[1137..1140] 144) (SYM:[1141..1144] +/-)
                          (CD:[1145..1146] 3))
                      (NNS:[1147..1151] days))))
                (-RRB-:[1151..1152] -RRB-))))))
      (CC:[1153..1156] and)
      (VP (VBN:[1157..1163] placed)
        (NP-1 (-NONE-:[1163..1163] *))
        (PP-LOC (IN:[1164..1166] in)
          (NP (JJ:[1167..1176] monolayer) (NN:[1177..1181] cell)
              (NN:[1182..1189] culture)))))
    (.:[1189..1190] .)))

;sentence 10 Span:1191..1314
;After 1  day in culture the cells were treated with ACTH (10 nM) with or
;without A-II  (0.1-100 nM) or TGF beta (1-100 pM).
;[1197..1198]:quantitative-value:"1"
;[1200..1203]:quantitative-units:"day"
;[1243..1247]:substance:"ACTH"
;[1249..1251]:quantitative-value:"10"
;[1252..1254]:quantitative-units:"nM"
;[1272..1276]:substance:"A-II"
;[1279..1286]:quantitative-value:"0.1-100"
;[1287..1289]:quantitative-units:"nM"
;[1294..1302]:substance:"TGF beta"
;[1304..1309]:quantitative-value:"1-100"
;[1310..1312]:quantitative-units:"pM"
(SENT
  (S
    (PP (IN:[1191..1196] After)
      (NP
        (NP (CD:[1197..1198] 1) (NN:[1200..1203] day))
        (PP-LOC (IN:[1204..1206] in)
          (NP (NN:[1207..1214] culture)))))
    (NP-SBJ-1 (DT:[1215..1218] the) (NNS:[1219..1224] cells))
    (VP (VBD:[1225..1229] were)
      (VP (VBN:[1230..1237] treated)
        (NP-1 (-NONE-:[1237..1237] *))
        (PP-MNR (IN:[1238..1242] with)
          (NP
            (NP (NN:[1243..1247] ACTH)
              (PRN (-LRB-:[1248..1249] -LRB-)
                (NP (CD:[1249..1251] 10) (NN:[1252..1254] nM))
                (-RRB-:[1254..1255] -RRB-)))
            (PP (IN:[1256..1260] with) (CC:[1261..1263] or)
                (IN:[1264..1271] without)
              (NP
                (NP (NN:[1272..1276] A-II)
                  (PRN (-LRB-:[1278..1279] -LRB-)
                    (NP
                      (QP (CD:[1279..1282] 0.1) (HYPH:[1282..1283] -)
                          (CD:[1283..1286] 100))
                      (NN:[1287..1289] nM))
                    (-RRB-:[1289..1290] -RRB-)))
                (CC:[1291..1293] or)
                (NP
                   (NN:[1294..1297] TGF) (SYM:[1298..1302] beta)
                  (PRN (-LRB-:[1303..1304] -LRB-)
                    (NP
                      (QP (CD:[1304..1305] 1) (HYPH:[1305..1306] -)
                          (CD:[1306..1309] 100))
                      (NN:[1310..1312] pM))
                    (-RRB-:[1312..1313] -RRB-)))))))))
    (.:[1313..1314] .)))

;sentence 11 Span:1315..1439
;Medium content of cortisol was low under  basal conditions, whereas
;ACTH-stimulated cortisol production by 10- to  100-fold.
;[1315..1321]:substance:"Medium"
;[1333..1341]:substance:"cortisol"
;[1383..1387]:substance:"ACTH"
;[1399..1407]:substance:"cortisol"
;[1422..1438]:quantitative-value:"10- to  100-fold"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1315..1321] Medium) (NN:[1322..1329] content))
      (PP (IN:[1330..1332] of)
        (NP (NN:[1333..1341] cortisol))))
    (VP (VBD:[1342..1345] was)
      (ADJP-PRD (JJ:[1346..1349] low))
      (PP (IN:[1350..1355] under)
        (NP (JJ:[1357..1362] basal) (NNS:[1363..1373] conditions)))
      (,:[1373..1374] ,)
      (SBAR-ADV (IN:[1375..1382] whereas)
        (S
          (NP-SBJ (NN:[1383..1387] ACTH))
          (HYPH:[1387..1388] -)
          (VP (VBN:[1388..1398] stimulated)
            (NP (NN:[1399..1407] cortisol) (NN:[1408..1418] production))
            (PP-EXT (IN:[1419..1421] by)
              (ADVP
                (QP (CD:[1422..1424] 10) (HYPH:[1424..1425] -)
                    (TO:[1426..1428] to) (CD:[1430..1433] 100)
                    (HYPH:[1433..1434] -) (RB:[1434..1438] fold))))))))
    (.:[1438..1439] .)))

;sentence 12 Span:1440..1512
;A-II and TGF beta inhibited ACTH-induced cortisol production by  70-90%.
;[1440..1444]:substance:"A-II"
;[1449..1457]:substance:"TGF beta"
;[1468..1472]:substance:"ACTH"
;[1481..1489]:substance:"cortisol"
;[1505..1511]:quantitative-value:"70-90%"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1440..1444] A-II))
      (CC:[1445..1448] and)
      (NP (NN:[1449..1452] TGF) (SYM:[1453..1457] beta)))
    (VP (VBD:[1458..1467] inhibited)
      (NP
        (ADJP (NN:[1468..1472] ACTH) (HYPH:[1472..1473] -)
              (VBN:[1473..1480] induced))
        (NN:[1481..1489] cortisol) (NN:[1490..1500] production))
      (PP (IN:[1501..1503] by)
        (NP
          (QP (CD:[1505..1507] 70) (HYPH:[1507..1508] -) (CD:[1508..1510] 90))
          (NN:[1510..1511] %))))
    (.:[1511..1512] .)))

;sentence 13 Span:1513..1653
;In addition, 3 days of treatment with ACTH caused a greater than 10-fold 
;induction of P-45017 alpha enzyme activity in fetal adrenal cells.
;[1526..1527]:quantitative-value:"3"
;[1528..1532]:quantitative-units:"days"
;[1551..1555]:substance:"ACTH"
;[1565..1585]:quantitative-value:"greater than 10-fold"
;[1600..1620]:cyp450:"P-45017 alpha enzyme"
(SENT
  (S
    (PP (IN:[1513..1515] In)
      (NP (NN:[1516..1524] addition)))
    (,:[1524..1525] ,)
    (NP-SBJ
      (NP (CD:[1526..1527] 3) (NNS:[1528..1532] days))
      (PP (IN:[1533..1535] of)
        (NP
          (NP (NN:[1536..1545] treatment))
          (PP (IN:[1546..1550] with)
            (NP (NN:[1551..1555] ACTH))))))
    (VP (VBD:[1556..1562] caused)
      (NP
        (NP (DT:[1563..1564] a)
          (QP (JJR:[1565..1572] greater) (IN:[1573..1577] than)
              (CD:[1578..1580] 10) (HYPH:[1580..1581] -) (JJ:[1581..1585] fold))
          (NN:[1587..1596] induction))
        (PP (IN:[1597..1599] of)
          (NP
             (NN:[1600..1607] P-45017) (SYM:[1608..1613] alpha)
             (NN:[1614..1620] enzyme)
            (NN:[1621..1629] activity))))
      (PP-LOC (IN:[1630..1632] in)
        (NP (JJ:[1633..1638] fetal) (JJ:[1639..1646] adrenal)
            (NNS:[1647..1652] cells))))
    (.:[1652..1653] .)))

;sentence 14 Span:1654..1753
;A-II and TGF  beta inhibited the ability of ACTH to induce P-45017 alpha
;activity by at least  75%.
;[1654..1658]:substance:"A-II"
;[1663..1672]:substance:"TGF  beta"
;[1698..1702]:substance:"ACTH"
;[1713..1726]:cyp450:"P-45017 alpha"
;[1749..1752]:quantitative-value:"75%"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1654..1658] A-II))
      (CC:[1659..1662] and)
      (NP (NN:[1663..1666] TGF) (SYM:[1668..1672] beta)))
    (VP (VBD:[1673..1682] inhibited)
      (NP
        (NP (DT:[1683..1686] the) (NN:[1687..1694] ability)
          (S-1 (-NONE-:[1694..1694] *ICH*)))
        (PP (IN:[1695..1697] of)
          (NP (NN:[1698..1702] ACTH)))
        (S-1
          (NP-SBJ (-NONE-:[1702..1702] *))
          (VP (TO:[1703..1705] to)
            (VP (VB:[1706..1712] induce)
              (NP
                 (NN:[1713..1720] P-45017) (SYM:[1721..1726] alpha)
                (NN:[1727..1735] activity))))))
      (PP (IN:[1736..1738] by)
        (NP
          (QP (IN:[1739..1741] at) (JJS:[1742..1747] least) (CD:[1749..1751] 75))
          (NN:[1751..1752] %))))
    (.:[1752..1753] .)))

;sentence 15 Span:1754..1946
;Using an antibody to P-45017 and immunoblotting techniques the effects of 
;ACTH, A-II, and TGF beta on enzyme activity were observed to correspond to 
;cellular levels of P-45017 alpha protein.
;[1763..1771]:substance:"antibody"
;[1775..1782]:cyp450:"P-45017"
;[1829..1833]:substance:"ACTH"
;[1835..1839]:substance:"A-II"
;[1845..1853]:substance:"TGF beta"
;[1857..1863]:cyp450:"enzyme"
;[1924..1945]:cyp450:"P-45017 alpha protein"
(SENT
  (S
    (S-MNR
      (NP-SBJ (-NONE-:[1754..1754] *))
      (VP (VBG:[1754..1759] Using)
        (NP
          (NP
            (NP (DT:[1760..1762] an) (NN:[1763..1771] antibody))
            (PP (TO:[1772..1774] to)
              (NP (NN:[1775..1782] P-45017))))
          (CC:[1783..1786] and)
          (NP (NN:[1787..1801] immunoblotting) (NNS:[1802..1812] techniques)))))
    (NP-SBJ-1
      (NP (DT:[1813..1816] the) (NNS:[1817..1824] effects))
      (PP (IN:[1825..1827] of)
        (NP
          (NP (NN:[1829..1833] ACTH))
          (,:[1833..1834] ,)
          (NP (NN:[1835..1839] A-II))
          (,:[1839..1840] ,) (CC:[1841..1844] and)
          (NP (NN:[1845..1848] TGF) (SYM:[1849..1853] beta))))
      (PP (IN:[1854..1856] on)
        (NP (NN:[1857..1863] enzyme) (NN:[1864..1872] activity))))
    (VP (VBD:[1873..1877] were)
      (VP (VBN:[1878..1886] observed)
        (S
          (NP-SBJ-1 (-NONE-:[1886..1886] *))
          (VP (TO:[1887..1889] to)
            (VP (VB:[1890..1900] correspond)
              (PP-CLR (TO:[1901..1903] to)
                (NP
                  (NP (JJ:[1905..1913] cellular) (NNS:[1914..1920] levels))
                  (PP (IN:[1921..1923] of)
                    (NP (NN:[1924..1931] P-45017) (SYM:[1932..1937] alpha)
                        (NN:[1938..1945] protein))))))))))
    (.:[1945..1946] .)))

;sentence 16 Span:1947..2043
;The inhibitory effects of TGF beta and  A-II could not be overcome by the
;cAMP analog (Bu)2cAMP.
;[1973..1981]:substance:"TGF beta"
;[1987..1991]:substance:"A-II"
;[2021..2025]:substance:"cAMP"
;[2026..2032]:substance:"analog"
;[2033..2042]:substance:"(Bu)2cAMP"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[1947..1950] The) (JJ:[1951..1961] inhibitory)
          (NNS:[1962..1969] effects))
      (PP (IN:[1970..1972] of)
        (NP
          (NP (NN:[1973..1976] TGF) (SYM:[1977..1981] beta))
          (CC:[1982..1985] and)
          (NP (NN:[1987..1991] A-II)))))
    (VP (MD:[1992..1997] could) (RB:[1998..2001] not)
      (VP (VB:[2002..2004] be)
        (VP (VBN:[2005..2013] overcome)
          (NP-1 (-NONE-:[2013..2013] *))
          (PP (IN:[2014..2016] by)
            (NP-LGS
              (NP (DT:[2017..2020] the) (NN:[2021..2025] cAMP)
                  (NN:[2026..2032] analog))
              (NP (NN:[2033..2042] -LRB-Bu-RRB-2cAMP)))))))
    (.:[2042..2043] .)))

;sentence 17 Span:2044..2184
;Interestingly, the  expression of the enzyme 3 beta-hydroxysteroid
;dehydrogenase was much less  sensitive to inhibition by A-II or TGF beta.
;[2082..2088]:substance:"enzyme"
;[2089..2124]:substance:"3 beta-hydroxysteroid dehydrogenase"
;[2167..2171]:substance:"A-II"
;[2175..2183]:substance:"TGF beta"
(SENT
  (S
    (ADVP (RB:[2044..2057] Interestingly))
    (,:[2057..2058] ,)
    (NP-SBJ
      (NP (DT:[2059..2062] the) (NN:[2064..2074] expression))
      (PP (IN:[2075..2077] of)
        (NP
          (NP (DT:[2078..2081] the) (NN:[2082..2088] enzyme))
          (NP (CD:[2089..2090] 3) (NN:[2091..2110] beta-hydroxysteroid)
              (NN:[2111..2124] dehydrogenase)))))
    (VP (VBD:[2125..2128] was)
      (ADJP-PRD
        (ADJP
          (ADVP (RB:[2129..2133] much) (RBR:[2134..2138] less))
          (JJ:[2140..2149] sensitive))
        (PP (TO:[2150..2152] to)
          (NP
            (NP (NN:[2153..2163] inhibition))
            (PP (IN:[2164..2166] by)
              (NP
                (NP (NN:[2167..2171] A-II))
                (CC:[2172..2174] or)
                (NP (NN:[2175..2178] TGF) (SYM:[2179..2183] beta))))))))
    (.:[2183..2184] .)))

;sentence 18 Span:2185..2409
;The ability of A-II and TGF beta to  suppress P-45017 alpha expression could
;play a role in determining the pathway  of steroidogenesis and specifically
;the amount of cortisol produced by fetal  adrenocortical cells in vivo.
;[2200..2204]:substance:"A-II"
;[2209..2217]:substance:"TGF beta"
;[2231..2244]:cyp450:"P-45017 alpha"
;[2352..2360]:substance:"cortisol"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[2185..2188] The) (NN:[2189..2196] ability)
        (S-1 (-NONE-:[2196..2196] *ICH*)))
      (PP (IN:[2197..2199] of)
        (NP
          (NP (NN:[2200..2204] A-II))
          (CC:[2205..2208] and)
          (NP (NN:[2209..2212] TGF) (SYM:[2213..2217] beta))))
      (S-1
        (NP-SBJ (-NONE-:[2217..2217] *))
        (VP (TO:[2218..2220] to)
          (VP (VB:[2222..2230] suppress)
            (NP
               (NN:[2231..2238] P-45017) (SYM:[2239..2244] alpha)
              (NN:[2245..2255] expression))))))
    (VP (MD:[2256..2261] could)
      (VP (VB:[2262..2266] play)
        (NP (DT:[2267..2268] a) (NN:[2269..2273] role))
        (PP (IN:[2274..2276] in)
          (S-NOM
            (NP-SBJ (-NONE-:[2276..2276] *))
            (VP (VBG:[2277..2288] determining)
              (NP
                (NP
                  (NP (DT:[2289..2292] the) (NN:[2293..2300] pathway))
                  (PP (IN:[2302..2304] of)
                    (NP (NN:[2305..2320] steroidogenesis))))
                (VBN:[2321..2324] and)
                (NP
                  (NP
                    (ADVP (RB:[2325..2337] specifically))
                    (DT:[2338..2341] the) (NN:[2342..2348] amount))
                  (PP (IN:[2349..2351] of)
                    (NP
                      (NP (NN:[2352..2360] cortisol))
                      (VP (VBN:[2361..2369] produced)
                        (NP (-NONE-:[2369..2369] *))
                        (PP (IN:[2370..2372] by)
                          (NP-LGS (JJ:[2373..2378] fetal)
                                  (JJ:[2380..2394] adrenocortical)
                                  (NNS:[2395..2400] cells)))
                        (ADVP (FW:[2401..2403] in) (FW:[2404..2408] vivo))))))))))))
    (.:[2408..2409] .)))

;section 19 Span:2413..2457
;PMID: 1655383 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2413..2417] PMID) (::[2417..2418] :) (CD:[2419..2426] 1655383)
        (IN:[2427..2428] -LSB-) (NNP:[2428..2434] PubMed) (HYPH:[2435..2436] -)
        (JJ:[2437..2444] indexed) (IN:[2445..2448] for)
        (NNP:[2449..2457] MEDLINE-RSB-)))
